home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

How to successfully create a Device History Record and keep FDA happy in the process - Webinar By GlobalCompliancePanel

 
  March 18, 2011  
     
 


GlobalCompliancePanel, Online Training Webinar
2011-04-27


Overview: Many companies are confident that their record keeping for the firm's device history records is compliant to the Quality System regulation, yet when the FDA comes calling, FDA 483 DHR cites are written and warning letters, seizures or worse ensue.

Internal Audits show the production controls system compliant, yet again FDA writes the firm up. This webinar will review the production records regulations; with an emphasis on just what is it that FDA is looking for. Emphasis will be placed on the Quality System Inspection Technique (QSIT) which FDA uses as an inspection tool.

Learning Objectives:
  • Learn what FDA expects and will request from you during your DHR review.
  • How QSIT inspections related to record keeping is performed by FDA.
  • How Change can affect DHRs.
  • Learn what constitutes a good DHR procedure.
  • Learn how risk management fits into DHR compliance.
  • Learn how to better audit quality record systems.
Areas Covered in the Session:
  • Introduction
  • Guidance documents/ QS regulation
  • Major FDA 483 points
  • Trends in FDA warning letters
  • Determining best practice for the DHR audit
  • Be prepared by knowing how to conduct a MORE thorough record audit
  • FDA 483 point issuance prevention
Who Will Benefit:
  • Senior executives of pharmaceutical and device firms
  • Quality Unit Vice Presidents
  • Directors and Managers
  • Vice presidents
  • Directors and Managers of operations
  • Quality Engineers and field Auditors
  • Regulatory and Compliance Management
  • Consultants
 
 
Organized by: GlobalCompliancePanel
Invited Speakers:
Nancy, is the Director of Quality & Regulatory Affairs, Healthcare responsible for global coordination of Celestica's Healthcare Quality, Regulatory and FDA compliance. Nancy is Quality and Regulatory expert with fifteen years experience in regulatory affairs, quality systems, compliance, clinical quality, validation, auditing, quality control, data management systems, post market surveillance, supplier management and regulatory compliance in the areas of bio/pharmaceuticals, medical devices and combination products. Nancy has contributed to the success of both venture and public companies, establishing a track record of successfully achieving timely global regulatory approvals, initiating and effectively managing preclinical and clinical investigations and developing and maintaining effective and compliant quality systems in various healthcare sectors.
 
Deadline for Abstracts: 2011-04-27
 
Registration: Price List:
Live : $245.00
Corporate live : $995.00
Recorded : $295.00
E-mail: webinars@GlobalCompliancePanel.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.